Mereo BioPharma Investors Face April Deadline in Setrusumab Securities Lawsuit
Rosen Law Firm urges MREO investors to act before April 6, 2026 deadline in securities class action alleging misleading clinical trial statements.
MREOsecurities class actionmisleading statements
